John Lechleiter on patent expiration
From Retired Eli Lilly CEO John Lechleiter Talks About His Life and Career · · Catholic Education Foundation
“The challenge we faced starting shortly after 2008 was we lost the patent exclusivity for basically our four largest products. We saw this coming in one case. They run out. There's a patent expiration date and of course generics enter the market quite quickly after that and your sales your revenue falls. We had the added problem of having some of our molecules that future drugs that were in development fail. So what we thought were going to be new drugs that would sort of enter our pipeline or come out of our pipeline to make up for the patents ended up not working. So we had to replenish the pipeline all the while we were losing revenue.”
On , John Lechleiter, Former Chairman, President & Chief Executive Officer at Lilly (Eli), spoke about patent expiration during Retired Eli Lilly CEO John Lechleiter Talks About His Life and Career on Catholic Education Foundation.
About John Lechleiter
John Lechleiter, former chairman and CEO of Eli Lilly, has remained active in public speaking and community engagement. In a 2020 discussion, he reflected on leadership during the COVID-19 pandemic, noting that enterprise risk management exercises at Fortune 500 companies in 2019 had not listed a pandemic as a risk. He also discussed Eli Lilly’s response to the loss of patents for products representing roughly 40% of 2009 sales, stating that the company chose to increase R&D investment despite falling revenue. Lechleiter expressed support for Indiana’s school voucher system, describing it as a “fairly progressive approach” to educational choice, and mentioned the Central Indiana Community Economic Relief Fund, which raised $23 million for pandemic relief. In a 2024 commencement address at Xavier University, his alma mater, Lechleiter urged graduates to be discerning, kind, generous, and courageous. He emphasized the importance of independent thinking and resisting the tendency to follow the crowd. In a 2025 TEDx talk, he discussed the concepts of mavericks, icons, and geniuses, citing figures such as Elon Musk, Steve Jobs, and Mother Teresa, and described his own role at Eli Lilly as an opportunity to contribute to the company’s mission of developing life-saving medicines. He also appeared in a 2024 video honoring the John C. Lechleiter Award, which recognizes Eli Lilly’s partnership with Providence Cristo Rey High School, a work-study program he helped establish.